Objectives: The rarity of temporal bone squamous cell carcinoma (TBSCC) precludes a clear understanding of the disease and approach to its management. This review provides general background on the disease and discusses the current and emerging oncologic and rehabilitative management options.
common temporal bone tumor histologic types, including both primary temporal bone tumors and those which affect it secondarily, are SCC (39%), basal cell carcinoma (14%), and adenoid cystic carcinoma (7%).
Given the paucity of temporal bone malignancies, there are few largescale studies and meta-analyses, no clinical trials, and substantially variable institutional management practices for TBSCC. As such, optimal treatment for the disease remains elusive. The goal of this review is to provide background on TBSCC, an overview of current and emerging oncologic and rehabilitative management practices for its treatment, and management recommendations based on the existing literature.
| METHODS
A PubMed literature review was performed to identify publications regarding TBSCC through August 2019. Search terms included combinations of the following phrases: "temporal bone," "squamous cell carcinoma," "malignancy," "cancer," "outcomes," "radiotherapy," "chemotherapy," "osseointegrated hearing aids," and "biomarkers." Each reference section was further reviewed to identify additional publications. Only articles published in the English-language were included.
2.1 | Primary origin, epidemiology, and etiology SCC can affect the temporal bone either primarily-within the ear canal, middle ear, or mastoid-or secondarily, from extratemporal sites. The extratemporal sites that most commonly infiltrate the temporal bone include the periauricular skin, auricular skin, parotid gland, and skull base. In a review of temporal bone malignancies, the periauricular skin and parotid gland were more common primary sites than the temporal bone itself. 5 The site of origin has important prognostic implications. Gidley et al 4 demonstrated higher overall survival (OS) and disease-free survival (DFS) rates for primary external auditory canal (EAC) tumors compared to auricular, periauricular, and parotid primary tumors affecting the temporal bone. SCC accounts for 60% to 80% of primary tumors of the temporal bone, while it makes up only around 40% of all tumors of the temporal bone. 4, 5 Finally, in most studies of TBSCC, approximately 60% of the patients are men and the most common age at diagnosis is 60 to 69 years, in accordance with most other epithelial malignancies. 6, 7 Unlike other head and neck cancers, tobacco and alcohol use do not appear to strongly increase the risk of primary TBSCC. 8 Prior radiation, however, does appear to be an important risk factor. Lo et al 9 reviewed their cohort of nasopharyngeal cancer patients who had received radiation treatment and found the incidence of subsequent EAC SCC to be 0.13%. This rate is nearly 1000 times higher than in the general population.
Chronic otitis media, otitis externa, and cholesteatoma have also been implicated as causes of primary TBSCC. 10 to be drawn. [14] [15] [16] Sun exposure is also a leading risk factor for TBSCC, as many of these tumors arise from auricular and periauricular skin. For most, however, the exact etiology remains elusive.
| Presentation and evaluation
Unfortunately, a significant overlap exists between benign and malignant otologic disease presentations. The three most common clinical findings of temporal bone malignancies are otalgia, otorrhea, and hearing loss, all of which are also commonly seen with benign diseases such as chronic otitis media or otitis externa. 17 The classic appearance of EAC SCC is an exophytic, ulcerated mass; however, because of similar symptomatology, cancer can be mistaken for inflammatory ear disease and thus allowed to grow unchecked. Eventually, findings suggestive of a more nefarious process, such as facial weakness and a parotid or neck mass, can arise. 4 Madsen et al 3 noted that symptoms of primary temporal bone tumors were present for an average of 13 months prior to presentation. It should be noted that inflammatory disease should resolve with aural cleaning, otic drops, and systemic antibiotics, but a lack of response should raise suspicion and prompt tissue sampling.
Careful otomicroscopic examination of the ear canal and tympanic membrane can aid in the diagnosis of an otologic malignancy; however, as the tumor grows, otomicroscopy can be limited by a mass preventing distal canal visualization ( Figure 1 ). As the majority of the temporal bone is regularly inaccessible from direct visualization, imaging plays a significant role in staging and management. Computed tomography (CT) and magnetic resonance imaging (MRI) provide complementary information regarding tumor extent. CT imaging can reliably detail erosion of the canal wall, labyrinth, petrous apex, or internal carotid artery and jugular bulb walls ( Figure 2 ). It can also provide excellent detail of the surrounding soft tissues and regional nodal basins. Contrast-enhanced MRI is especially helpful in identifying perineural disease or dural involvement. 5, [18] [19] [20] Accordingly, both CT and MRI are essential for correct tumor staging. An accurate assessment of tumor spread is critical, given that a principal prognostic factor for TBSCC is the degree of local tumor extension. 20 Finally, positron emission tomography should be utilized in patients with advanced disease to identify and evaluate distant metastases. 10,17
| Spread of disease and the Pittsburgh staging system
In theory, the bony construct of the temporal bone should provide good protection from local tumor spread, as bone is generally a good tumor barrier; however, there are many natural pathways within the temporal bone that allow easy spread of disease. Leonetti et al 21 Although the American Joint Committee on Cancer (AJCC) has a staging system for most head and neck malignancies, it lacks one for primary temporal bone malignancies. For primary tumors of other sites that invade the temporal bone, the AJCC staging system for that site is used, such as for parotid tumors and periauricular skin cancers.
For primary temporal bone malignancies, however, the most widely The scan also revealed that the tumor was destroying the bony ear canal (arrowhead). C, Coronal computed tomography scan shows the extent of disease in the upper neck and paraspinous muscles (arrow). The patient was given palliative treatment and died 2 months later used staging system is the Pittsburgh staging system (PSS), which was originally published by Arriaga et al 20 in 1990 . Although the PSS is based on data from patients with SCC, it is currently used to stage other tumor histologic types as well. It utilizes the familiar tumornode-metastasis (TNM) format and uses CT findings of bony EAC destruction, surrounding soft tissue infiltration, and medial bony temporal structure involvement to place patients in equitable treatment and prognostic groups. The TNM system can be converted into the four-stage system used for other head and neck cancers in standard fashion, with the exception that any temporal bone malignancy with lymph node involvement is automatically considered stage IV. 20 This conversion system reflects the better prognosis for tumors limited to the EAC (T1 or T2 disease) and the poorer prognosis for tumors involving the middle ear or mastoid (certain T3 or T4 disease). 3 Moody et al 1 added tumors with facial nerve involvement to the T4 category given the poor outcomes of their patients with facial paresis. Since 2000, there have been suggested variations to the PSS, but none have been widely adopted in the literature. 24 
| Management of the temporal bone
The standard of care for the oncologic management of TBSCC is surgery. 26 There are three options for resection: lateral temporal bone resection (LTBR), subtotal temporal bone resection (STBR), and total temporal bone resection (TTBR). All of these procedures take advantage of the anatomy of the temporal bone in establishing tumor-free margins and can be performed either en bloc or in piecemeal fashion.
LTBR is the most widely used approach for otologic oncologic surgery. Predominately performed en bloc, it is the removal of the ear canal lateral to the facial nerve and stapes. Specifically, the EAC, tympanic membrane, malleus, and incus are removed, preserving the inner ear. As such, LTBR is typically used for cancer that has not invaded the middle ear or mastoid. Because LTBR involves disruption of the natural sound conduction mechanism, patients can expect maximal conductive hearing loss post-operatively. Recently, Ghavami et al 29 proposed a modified LTBR with the goal of preserving conductive hearing in TBSCC patients with very limited bony canal involvement. They performed a standard LTBR but preserved the tympanic membrane and ossicles and reconstructed the remaining EAC with a split-thickness skin graft. The mean post-operative air-bone gap was 9 dB, significantly less than expected after a true LTBR. 30 However, the generalizability of these results is limited by the fact that the study only included five patients with a mean post-operative follow-up of 29 months.
STBR can be performed when disease extends past the tympanic membrane into the middle ear or mastoid. At its core, this procedure is a LTBR with additional removal of the bony labyrinth; thus, it sacrifices sensorineural hearing and, often, facial nerve function. 24 However, a landmark study by Prasad and Janecka 31 demonstrated a survival benefit in patients with disease extending into the middle ear who underwent STBR rather than LTBR. Furthermore, STBR can be executed en bloc or piecemeal. To date, there is no literature demonstrating improved outcomes with en bloc vs piecemeal resection, but some still advocate for a "no touch" en bloc procedure to obtain negative margins. 32, 33 Given the substantial exposure of STBR and the proximity of neurovascular structures, such as the jugular bulb and internal carotid artery, many surgeons elect to perform STBR in a piecemeal fashion to reduce morbidity. 17, 22 TTBR is a STBR with additional removal of the petrous apex and internal auditory canal. It may be considered when malignancy spreads into or medial to the bony labyrinth. Both en bloc and piecemeal excisions have been described. En bloc TTBR involves resection of the internal carotid artery, cranial nerves VI through XII, and surrounding structures. 34 Given the morbidity associated with this procedure and the lack of a proven survival benefit when compared with less aggressive resections, many authors believe that TTBR is not justified, and it is rarely performed today. 31, 32 A surgical alternative to TTBR is STBR with selective piecemeal excision beyond STBR's normal boundaries. 19, 32 Regardless of approach, patients with T4 tumors generally have a dismal prognosis when treated with TTBR and radiotherapy. 1 In these advanced cases, chemotherapy has recently gained attention as an attractive substitute for surgery and radiotherapy. All three types of temporal bone resection permit adequate exposure for dural resection. The extent of dural resection is based on margin status and is repaired with a dural substitute. 35 Resection of the internal carotid artery is also an option, but it can add significant morbidity and has not been shown to improve survival. 31, 36 Absolute contraindications to curative surgery are poor health, cavernous sinus involvement, unresectable neck disease, and distant metastases. 5 Relative contraindications include carotid artery and lower cranial nerve involvement. 37 One last resection option described in the literature is a local canal resection (LCR), also termed a "sleeve resection." This procedure generally involves removal of the skin from the bony ear canal and reconstruction of the EAC with a split-thickness skin graft. 
| Management of extratemporal structures
Temporal bone resection can be combined with parotidectomy and neck dissection for adequate staging and control of extratemporal disease.
Given the pathways of the temporal bone-such as the fissures of
Santorini-and the lymphatic drainage from the EAC, most authors con- 40, 44 Given its proximity to the parotid and EAC, the TMJ is also vulnerable to invasion. Most authors advocate for mandibular condylectomy in patients with T3 or T4 EAC SCC, but the procedure is controversial in patients with early disease. 45 
| Reconstruction
Reconstruction of temporal defects is critical to appropriate healing and prevention of complications. For most LTBR defects, a temporalis muscle flap suffices. 47 The temporalis muscle depends on the deep temporal artery for its blood supply. If this artery is damaged, then an alternate means of reconstruction is required. For larger defects, such as STBR defects or those resulting from auriculectomy and condylectomy, a microvascular free flap may be required. 17 In such cases, the anterolateral thigh is the most common source because it provides bulk and sufficient skin coverage. 44 If the facial nerve is sacrificed in a patient with normal preoperative facial function, immediate nerve grafting is recommended. 44 Facial function after nerve grafting does not appear to be affected by postoperative radiotherapy. 48 
| Role of radiotherapy and chemotherapy
Radiotherapy for TBSCC is most commonly given in the adjuvant postoperative setting. Indications for postoperative radiotherapy include lymph node metastasis, perineural invasion, positive margins, recurrent tumors, and bone invasion. 1, 8, 22, 39, 45 Most authors agree that radiotherapy is not a substitute for obtaining negative margins. 20 Multiple studies have also demonstrated improved survival rates with adjuvant radiotherapy as opposed to surgery alone for T2 and higher tumors, since T2 tumors by definition have bone invasion. 1, 22, 38, 53, 54 Little benefit of postoperative radiotherapy has been seen for patients with completely resected T1 tumors. 54 This difference highlights the need for proper staging. 32, 38 Chemotherapy is an emerging modality in the treatment of TBSCC.
Historically used only for advanced tumors in the adjuvant setting, its use as an induction agent is promising. Nakagawa et al 18 65 Complication rates do not appear to be different in otologic oncology patients compared to the general population with OIHAs. 65, 66 Nader et al 65 evaluated OIHA implantation in temporal bone cancer patients and determined that, to decrease complication rates, the ideal timing of implantation is at initial oncologic resection and prior to radiotherapy, if possible. The authors also recommend waiting 6 months prior to loading with the processor.
Finally, there have been reports of promising results from conductive hearing restoration surgery, such as tympanoplasty, performed at the time of initial oncologic resection. 64 
| Biomarkers
As patients with advanced TBSCC face poor outcomes, various biomarkers have been investigated to improve prognostication and surveillance. MASPIN (MAmmary Serine Protease INhibitor) is a tumor suppressor gene found to have increased levels of cytoplasmic expression in patients without TBSCC recurrence. 67 Marioni et al 68 also displayed a significantly increased recurrence rate and shorter DFS in TBSCC that had increased expression of endoglin (CD105), a proliferation-associated protein expressed in angiogenic endothelial cells. Finally, expression of epidermal growth factor receptor has recently been associated with poor survival outcomes. 69 These biomarkers may provide avenues to identify patients at high risk for
recurrence. Other biomarkers have also been studied but have not been found to correlate statistically with survival. [70] [71] [72] [73] 3 | CONCLUSION Although SCC is the most common malignancy of the temporal bone, it is seen only rarely in clinical practice. This has limited the ability to perform randomized trials and agree upon a management strategy.
Because of the aggressive nature of the tumor, the typically late stage at presentation, and the anatomic peculiarities of the temporal bone,
TBSCC treatment is complex and should be delivered by a multidisciplinary team. LTBR remains at the heart of treatment for ear canal tumors, and postoperative radiotherapy is typically given to patients with tumors at stage T2 and higher. Novel surveillance and treatment strategies are emerging for advanced tumors, but multi-institutional research collaboration efforts may prove most beneficial in defining a management algorithm for TBSCC.
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